Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni, Daniele Generali, Katia Cagossi, Samanta Sarti, Antonio Frassoldati, Lorenzo Gianni, Luigi Cavanna, Graziella Pinotti, Antonino Musolino, Federico Piacentini, Saverio Cinieri, Aleix Prat, PierFranco Conte